allogeneic CAR T-cell therapy (Mesoblast)

N/A

Report date: 2025/03/14 16:20:47

Base Information

Drug Nameallogeneic CAR T-cell therapy (Mesoblast)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunostimulantsT lymphocytes stimulants

TargetsUpdating

Therapy Area/IndicationsOvarian NeoplasmsStomach Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia and New Zealand

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesMesoblast Ltd

China Registration ClassN/A

Develop Information

Active CompaniesMesoblast Ltd

Inactive CompaniesN/A

Active IndicationsOvarian NeoplasmsStomach Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A